ZYME - Bragar Eagel & Squire P.C. Is Investigating Zymeworks Regeneron Jabil and DoubleVerify and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ:ZYME), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Jabil Inc. (NYSE:JBL), and DoubleVerify Holdings, Inc. (NYSE:DV). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Zymeworks Inc. (NASDAQ:ZYME)
On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately. Notably, although Zymeworks indicated that it had appointed current President and Chief Executive Officer Kenneth Galbraith as Interim CFO and had initiated a search for a new CFO, the Company failed to provide any reasoning for Astle's removal as SVP and CFO.
On this news, Zymeworks's stock price fell $0.64 per share, or ...